These results underscore the critical role of METTL14 in the survival and growth of MDS cells, highlighting the potential therapeutic value of targeting the METTL3-METTL14 complex-mediated m6A modification in MDS. This evidence concerns the gene METTL3 and myelodysplastic syndrome.